

CTI's Pre-Proposal Guidelines



What CTI Looks For

- Strong Project Rationale
 - Demonstrated association between target biology, pathway and disease mechanism
 - Target validation as demonstrated by genetic or pharmacologic evidence
- Therapeutic Area Opportunity
 - Unmet medical needs, opportunity for novel therapeutic mechanism or modality
- Therapeutic Drug Target
 - Novel target, novel therapeutic strategy or new insight into target patient population
 - Defined target
 - Demonstrated cause/effect relationship to disease mechanism
 - Understanding of desired pharmacology
 - Tractability of target relative to drug modalities (monoclonal antibodies, peptides, proteins or small molecules), available reagents, assays and technologies
- Project Feasibility
 - Clear path to candidate development (biochemical/cell-free/cellular assays, disease models, preclinical testing, etc.)
 - Clear path to FIH clinical trial (approach for proof-of-mechanism in humans, accessible patient population, timeframe, safety issues, etc.)
- Ability to Translate Basic Biological Research into the Clinic
 - From molecular mechanism to therapeutic opportunity
 - Personalized medicine, patient stratification, molecular signatures, genetic associations, biomarkers

What CTI Does Not Look For

- Target Discovery
 - Technologies or projects looking for new target
- Exploratory Research
 - Development of animal models, cell line models, indication expansion or mechanism of action for existing drugs
- Platform Technology
 - Vaccine platform, RNAi platform, screening platform
- Pre-clinical or Clinical Drug Candidates
 - IND-ready candidates or clinical trials candidates
 - Note: *CTI may consider proposals for pre-existing drug candidates based upon discussions with PI and Technology Transfer Office*
- In-licensing Opportunities